Application of berberine in medicine for treating non-alcoholic fatty liver disease

A technology for non-alcoholic and fatty liver disease, which is applied in the application field of berberine in the treatment of non-alcoholic fatty liver disease, and can solve problems such as unknown effects and unknown fatty liver

Inactive Publication Date: 2013-11-20
RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

(4) Treatment of fatty liver: BBR has shown significant efficacy in the treatment of fatty liver in obese mice and high-fat-fed rats, but whether it has the effect of treating non-obese NAFLD remains unknown
More strikingly, BBR showed significant efficacy in treating fatty liver in obese mice and high-fat-fed mice, however, whether it has the effect of treating fatty liver in non-obese mice remains unknown, it simulated in vitro Whether it also has a therapeutic effect in the model remains to be further studied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of berberine in medicine for treating non-alcoholic fatty liver disease
  • Application of berberine in medicine for treating non-alcoholic fatty liver disease
  • Application of berberine in medicine for treating non-alcoholic fatty liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018] Below in conjunction with embodiment, the present invention will be further described:

[0019] Choline and methionine deficiencies in the MCD diet. MCD diet can lead to the accumulation of TG in the liver by inhibiting the β-oxidation of mitochondrial fatty acids and the output of VLDL, which can cause fat accumulation, inflammation and liver fibrosis in the liver in a short time. It is a widely used in the study of NAFLD and Fatty liver model of NASH. Among them, choline has an affinity for fat, which can promote fat to be transported from the liver through the blood in the form of phospholipids or improve the utilization of fatty acids in the liver, and prevent abnormal accumulation of fat in the liver. If the body lacks choline, fat will accumulate in the liver and fatty liver will appear, which is a sick condition. Clinically, choline is used to treat liver cirrhosis, hepatitis and other liver diseases, and the effect is good. Methionine is a sulfur-containing e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicine preparation and particularly relates to an application of berberine in a medicine for treating non-alcoholic fatty liver disease. According to the invention, db / db mouse with diabetic obesity and NAFLD (Non-Alcoholic Fatty Liver Disease) is employed to simulate a fat NAFLD patient, and a mouse with non-obese fatty liver caused by methionine-choline deficient (MCD) is used as a model to simulate a non-fat NAFLD patient so as to observe the effect of BBR. Shown by all test results, the BBR not only can reduce the weight of the obese mouse and improve the glycometabolism and lipid metabolism, but also can treat the concurrent fatty liver of the obese mouse, and also has obvious treatment effect on the fatty liver of the non-obese mouse, and the results are verified in a cell model simulated in vitro, so that the BBR has obvious treatment effect on the obesity and the non-obese NAFLD surely and can be used in preparation of the medicine for treating the NAFLD.

Description

technical field [0001] The invention belongs to the field of medicine preparation, and particularly relates to the application of berberine in medicine for treating nonalcoholic fatty liver disease. Background technique [0002] Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by excessive deposition of triglyceride (Tglyceride, TG) in liver cells. Highly popular. [0003] When the weight of liver triglyceride exceeds 5% of the weight of the liver, and under the light microscope, more than 30% of the hepatic parenchymal cells have fatty changes per unit area, it is considered that non-alcoholic fatty liver is formed. NAFLD is the most common cause of abnormal liver function enzymes and chronic liver disease in Western developed countries such as Europe and the United States. The prevalence of NAFLD in ordinary adults is 15%-40%, and the prevalence of NAFLD in obese patients is 60%-95%. Type 2 diabetes The prevalence of NAFLD in patients with hyperlipide...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61P1/16
Inventor 宁光李博李小英洪洁王卫庆杨颖张志国
Owner RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap